

substantial number of small entities because the rule only affects the operations of NASA and its employees. Accordingly, no regulatory flexibility analysis is required.

#### *Executive Order 12866 Determination*

This rule is not a “significant regulatory action” under section 3(f) of Executive Order 12866, Regulatory Planning and Review, is not subject to review under section 3(d) of that Order because it is limited to NASA’s organization, management and/or personnel matters, and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order.

#### *Collection of Information*

This rule calls for no new collection of information under the Paperwork Reduction Act (44 U.S.C. 3501–3520).

#### *Federalism*

A rule has implications for federalism under Executive Order 13132, Federalism, if it has a substantial direct effect on State or local governments and would either preempt State law or impose a substantial direct cost of compliance on them. NASA has analyzed this rule under that Order and has determined that it does not have implications for federalism.

#### *Unfunded Mandates Reform Act*

Title II of the Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531–1538) requires Federal agencies to assess the effects of their discretionary regulatory actions. NASA has determined that the rule will not result in expenditures by State, local, or tribal governments or by the private sector of \$100 million or more. The rule affects only the internal organization of NASA. Accordingly, NASA has not prepared a budgetary impact statement or specifically addressed regulatory alternatives.

#### **List of Subjects in 14 CFR Part 1204, Subpart 5**

Administrative practice and procedure, Authority delegations (Government agencies), Civil rights, Labor management relations, Organization and functions (Government agencies), Real property acquisition.

#### **Sean O’Keefe,**

*Administrator, National Aeronautics and Space Administration.*

For the reasons set out in the preamble, NASA amends 14 CFR part 1204, subpart 5, as follows:

## **PART 1204—ADMINISTRATIVE AUTHORITY AND POLICY**

### **Subpart 5—Delegations and Designations**

1. The authority citation for subpart 5 is revised to read as follows:

**Authority:** 42 U.S.C. 2473; 36 U.S.C. 143.

2. Add § 1204.506 to subpart 5 to read as follows:

#### **§ 1204.506 Delegation of authority to license the use of the Centennial of Flight Commission name.**

(a) *Delegation of authority.* The Assistant Administrator for Public Affairs is delegated the authority of section 9 of the Centennial of Flight Commemoration Act, as amended (Pub. L. 105–389) to license the use of the Centennial of Flight Commission name on any logo, emblem, seal, or descriptive or designating mark adopted for use by the Administrator in commemorating the centennial of powered flight.

(b) *Redelegation.* The authority delegated in paragraph (a) of this section may not be redelegated.

[FR Doc. 02–17989 Filed 7–17–02; 8:45 am]

**BILLING CODE 7510–01–P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Food and Drug Administration**

#### **21 CFR Part 558**

#### **New Animal Drugs for Use in Animal Feeds; Diclazuril and Bacitracin Methylene Disalicylate**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The NADA provides for use of approved single-ingredient diclazuril and bacitracin methylene disalicylate Type A medicated articles to make two-way combination drug Type C medicated feeds for growing turkeys.

**DATES:** This rule is effective July 18, 2002.

#### **FOR FURTHER INFORMATION CONTACT:**

Charles J. Andres, Center for Veterinary Medicine (HFV–128), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–1600, e-mail: candres@cvm.fda.gov.

**SUPPLEMENTARY INFORMATION:** Schering-Plough Animal Health Corp., 1095 Morris Ave., P.O. Box 3182, Union, NJ 07083, filed NADA 141–194 that provides for use of CLINACOX (0.2 percent diclazuril) and BMD (10, 25, 30, 40, 50, 60, or 75 grams per pound (g/lb) bacitracin methylene disalicylate) Type A medicated articles to make two-way combination drug Type C medicated feeds for growing turkeys. The Type C feeds contain 0.91 g/ton diclazuril and 4 to 50 g/ton bacitracin methylene disalicylate, and they are used for the prevention of coccidiosis caused by *Eimeria adenoeides*, *E. gallopavonis*, and *E. meleagriditis*, and for increased rate of weight gain and improved feed efficiency. The NADA is approved as of April 2, 2002, and the regulations are amended in 21 CFR 558.198 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of each application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(2) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

#### **List of Subjects in 21 CFR Part 558**

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

#### **PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**

1. The authority citation for 21 CFR part 558 continues to read as follows:

**Authority:** 21 U.S.C. 360b, 371.

2. Section 558.198 is amended by adding paragraph (d)(2)(ii) to read as follows:

**§ 558.198 Diclazuril.**

(2) \* \* \*

\* \* \* \* \*

(d) \* \* \*

Diclazuril grams/ton	Combination grams/ton	Indications for use	Limitations	Sponsor
<p>(ii) 0.91 (1 ppm).</p>	<p>Bacitracin methylene disalicylate 4 to 50.</p>	<p>Growing turkeys: As in paragraph (d)(2)(i) of this section; for increased rate of weight gain and improved feed efficiency.</p>	<p>As in paragraph (d)(2)(i) of this section. Bacitracin methylene disalicylate provided by No. 046573 in § 510.600(c) of this chapter.</p>	<p>000061</p>

Dated: July 8, 2002.

**Stephen F. Sundlof,***Director, Center for Veterinary Medicine.*

[FR Doc. 02-18119 Filed 7-17-02; 8:45 am]

BILLING CODE 4160-01-S

**AGENCY FOR INTERNATIONAL DEVELOPMENT****22 CFR Part 213****Claims Collection****AGENCY:** Agency for International Development ("USAID").**ACTION:** Final rule.

**SUMMARY:** USAID is revising its regulation on Claims Collection in its entirety to incorporate applicable statutory and regulatory provisions and to make other changes.

**DATES:** Effective Date: July 18, 2002.**FOR FURTHER INFORMATION CONTACT:** Mr. Joe Keady, 202-712-5744.**SUPPLEMENTARY INFORMATION:****A. Background**

USAID is revising its claim collection procedures to incorporate changes made to the Federal Claims Collection Standards and the Debt Collection Improvement Act of 1996. One principal change in the rule is the provision for the mandatory referral of certain delinquent debt to the Federal Management Service of the Department of the Treasury. The changes will maximize the effectiveness of USAID's claim collection procedures.

**B. Regulatory Analysis***Executive Order 12866*

USAID has determined that this regulation is not a significant regulatory action as defined in Executive Order 12866 and, accordingly, this regulation has not been reviewed by the Office of Management and Budget.

*Regulatory Flexibility Act*

It is hereby certified that this regulation will not have a significant economic impact on a substantial number of small entities. Accordingly, a

Regulatory Flexibility Analysis is not required.

*Executive Order 13132*

This regulation will not have a substantial direct effect on the states, on the relationship between the national government and the states, or on distribution of power and responsibilities among the various levels of government. Therefore, in accordance with Executive Order 13132, it is determined that this regulation does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

*Unfunded Mandates Reform Act of 1995*

This regulation will not result in the expenditure by state, local and tribal governments, in the aggregate, or by the private sector, of \$100 million or more in any one-year, and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

*Small Business Regulatory Enforcement Fairness Act of 1996*

This rule is not a major rule as defined by section 251 of the Small Business Regulatory Enforcement Act. 5 U.S.C. 804. This rule will not result in an annual effect on the economy of \$100 million or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic or export markets.

*Executive Order 12988—Civil Justice Reform*

USAID has conducted the reviews required by section 3 of Executive Order 12988 and has determined that, this rule meets the applicable standards in section 3 to mitigate litigation, eliminate ambiguity and reduce burden.

*Paperwork Reduction Act*

This rule does not contain information collection requirements that require approval by the Office of Management and Budget under the Paperwork Reduction Act (44 U.S.C. 3507 *et seq.*).

**List of Subjects in 22 CFR Part 213**

Administrative practice and procedure, Claims, Federal employees, Fraud, Penalties, Privacy.

**Authority and Issuance**

For the reasons set out in the preamble, part 213 of Title 22 is revised as follows:

**PART 213—CLAIMS COLLECTION****Subpart A—General**

Sec.

- 213.1 Purpose and scope.
- 213.2 Definitions.
- 213.3 Loans, guarantees, sovereign and interagency claims.
- 213.4 Other remedies.
- 213.5 Fraud claims.
- 213.6 Subdivision of claims not authorized.
- 213.7 Omission not a defense.

**Subpart B—Collection**

- 213.8 Collection—general.
- 213.9 Written notice.
- 213.10 Review requirements.
- 213.11 Aggressive collection actions; documentation.
- 213.12 Interest, penalty and administrative costs.
- 213.13 Interest and charges pending waiver or review.
- 213.14 Contracting for collection services.
- 213.15 Use of credit reporting bureaus.
- 213.16 Use and disclosure of mailing addresses.
- 213.17 Liquidation of collateral.
- 213.18 Suspension or revocation of eligibility for loans and loan guarantees, licenses or privileges.
- 213.19 Installment payments.

**Subpart C—Administrative Offset**

- 213.20 Administrative offset of non-employee debts.
- 213.21 Employee salary offset—general.
- 213.22 Salary offset when USAID is the creditor agency.
- 213.23 Salary offset when USAID is not the creditor agency.